For more information on the Phase 1b clinical trial, visit: https://clinicaltrials.gov/study/NCT06732180 ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

Bank of New York Mellon Corp increased its holdings in Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) by 15.6% during ...

Cryotherapy is emerging as a promising strategy to prevent chemotherapy-induced peripheral neuropathy, but adoption in clinical practice remains limited.

A stem cell therapy trial aimed at reducing neuroinflammation in patients with presymptomatic Alzheimer's disease is underway at UTHealth Houston.

Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials ...

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at William ...

Vigil is the first cellular immunotherapy to demonstrate longer-term survival benefits in a randomized controlled trial of patients with solid tumors. The results of the company's Phase 2b study have ...

INVINCIBLE-3 Study, and 25 patients have been screened Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several ...

RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program ...

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jason C. Foster, CEO of Ori Biotech, ...

Explore effective feeding strategies for dairy cows during critical transition periods. Learn from experts about DCAD and mineral binders.